DEM Biopharma, Inc. Alternatives & Competitors
12 companies similar to DEM Biopharma, Inc. — Novel Target for Solid Tumors
Companies similar to DEM Biopharma, Inc.
LAVA Therapeutics N.V.
Developing next generation bispecific gamma-delta T cell engaging (bsTCE) antibodies to fi...
Utrecht, The Netherlands
NextPoint Therapeutics, Inc.
Launching a new world of precision therapeutics through its leading scientific work on th...
ADC Therapeutics
Innovating Science. Inspiring Hope.
Lausanne, Switzerland
Pheon Therapeutics
Pheon is an Antibody-Drug Conjugate specialist developing next generation ADCs for a range...
London, United Kingdom
Rival Readout
Competing with DEM Biopharma, Inc.? We do this properly.
10 rivals, 90 days of dated moves, ranked by what matters and sourced, in 7 business days.
Elevation Oncology
We are focused on discovering and developing selective cancer therapies to treat patients...
Boston, United States
Myricx Bio
Developing a new class of ADCs based on NMT inhibition to treat cancer
London, United Kingdom
Brenus Pharma
Next-generation cancer treatment bringing the immune system one step ahead of cancer 🧬🟣
Lyon, France
TenSixty Biosciences
We're on a mission to create transformative drugs that will save lives and redefine oncolo...
Bolt Biotherapeutics, Inc.
Plans to develop a novel format for T-cell mediated anti-tumour therapy
Redwood City, United Stat...
Apexigen
Creating Transformative Immunotherapies for Patients with Cancer
San Carlos, United States
Cure51
We want every patient to become a Cancer Survivor.
Paris, France
FogPharma
Until everything is druggable.
Cambridge, United States
About DEM Biopharma, Inc.
DEM Biopharma, Inc., established in 2022, is a cutting-edge player in the Biotechnology, Life Sciences, and Pharmaceutical sectors, headquartered in the United States. The company is focused on developing innovative cancer treatments with a lead program, DEM301, an antibody-drug conjugate (ADC) that targets a novel ext...
Research and Development, Poster Presentation, Therapeutics Innovation
Healthcare Professionals, Oncologists, Medical Researchers, Hospitals, Pharmaceutical Companies
Cancer Therapeutics, Immuno-Oncology, Antibody-Drug Conjugate, Solid Tumors, Extracellular Protein Targeting, Gastrointestinal Malignancies, Innate Immune System Checkpoints, Biopharmaceuticals, Oncology Innovation, Novel Cancer Targets, ADC Development
B2B
Licensing, Product Sales, Performance Based
Frequently Asked Questions
From the desk
Mapping a market? Start with a Rival Readout.
In 7 business days we read 10 rivals around DEM Biopharma, Inc.: 90 days of dated moves, ranked by what matters to you, each with its source. Fully credited if you continue.
Compiled from the BounceWatch company index. We last looked at DEM Biopharma, Inc. on 18 Mar 2026. The 12 companies listed here were last checked between 12 Sep 2024 and 25 Aug 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
